Biotechnology is one of the most dynamic fields in the global economy, with breakthroughs promising to reshape healthcare and improve millions of lives. But behind the science lies an often-overlooked truth: innovation requires capital. Not just any capital, but patient, strategic investment that recognizes the unique challenges of developing therapies. For Leen Kawas, co-founder and managing general partner of Propel Bio Partners, this understanding is central to her work.
Leen Kawas brings a rare combination of perspectives to the world of biotech investment. She is not only a venture capitalist but also a scientist, inventor, and entrepreneur. Having co-founded Athira Pharma and led it through late-stage clinical trials and a $400 million public offering, she has lived the journey of translating discovery into product. Her conviction today is clear: life science does not thrive on short-term bets but on smart, steady capital that can see the process through.
The Long Arc of Innovation
Kawas emphasizes that developing a therapy is unlike building a typical startup. The path from early research to regulatory approval spans years, often decades. Clinical trials are expensive, regulatory requirements are exacting, and setbacks are common.
She explains that investors accustomed to rapid exits in software or consumer technology often struggle with the patience life science demands. In biotech, failure to recognize this long arc can undermine promising science. Patient capital, by contrast, enables researchers and entrepreneurs to navigate inevitable hurdles without sacrificing the integrity of their work.
Smart Capital as a Catalyst
For Kawas, patience alone is not enough. She stresses the need for “smart capital”—investment paired with expertise, networks, and guidance. Propel Bio Partners was founded on this principle. The firm does more than provide financing; it offers strategic support to help companies anticipate challenges, refine strategies, and connect with the right partners.
Kawas draws on her own experience leading Athira Pharma. She recalls that access to knowledgeable investors and advisors often made the difference between progress and stagnation. Smart capital, she argues, is catalytic: it multiplies the impact of financial investment by ensuring companies can execute effectively.
Broadening Access to Innovation
Another dimension of Kawas’s philosophy is her focus on expanding opportunities for diverse founders. She notes in this interview with Billion Success that many brilliant scientists lack the networks or financial backing to advance their work. Without intervention, valuable discoveries can languish in laboratories rather than reaching patients.
Through Propel Bio Partners, she works to close this gap by backing founders who might otherwise be overlooked. Her belief is that broadening access to capital is not just an equity issue but a way to accelerate innovation across the sector. When more perspectives and ideas are supported, the chances of breakthrough therapies increase.
From Science to Business
Kawas’s perspective is shaped by her journey as a scientist turned entrepreneur. At Athira Pharma, she helped advance therapies targeting neurodegenerative diseases, guiding the company from early development through an IPO. That experience underscored for her the unique challenges of turning science into business: securing funding, meeting regulatory standards, and managing growth while preserving scientific integrity.
She emphasizes that life science founders often need guidance on this transition. Patient, smart capital helps bridge the gap between laboratory discovery and market delivery. Investors who understand both science and business can create conditions where innovation is not only possible but sustainable.
Aligning Capital With Purpose
Kawas often points out that life science investment carries a dual responsibility. It must deliver returns to investors, but it must also serve patients. The stakes are measured not only in dollars but in lives improved or saved. For her, this dual purpose reinforces the need for disciplined, mission-driven capital.
She argues that when investors align with this purpose, they create healthier companies and healthier industries. The most successful biotech ventures are not those that chase quick wins, but those that build enduring value by delivering therapies that matter.
A Vision for the Future
Looking ahead, Kawas envisions a biotech ecosystem where capital is both abundant and discerning. She hopes to see more investors adopt the principles of patience and strategy, recognizing that the rewards of life science are both financial and societal.
Through Propel Bio Partners, she continues to back companies that embody this vision—ventures with strong science, committed teams, and the potential to transform patient care. For Kawas, the lesson is simple: life science is too important for short-term thinking. It requires capital that is not only willing to wait but willing to think.
Leen Kawas is currently on the board of directors for Inherent Biosciences: